To appraise the clinical and cost effectiveness of letermovir within its marketing authorisation for preventing cytomegalovirus reactivation or disease in people with sero-positive-CMV who have had an allogeneic haematopoietic stem cell transplant.
 
Status Proposed
Process STA
ID number 1153

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Merck, Sharp & Dohme (letermovir)
Others Department of Health
  NHS England
  NHS Barnet CCG
  NHS East and North Hertfordshire CCG
  Welsh Government
Patient carer groups African Caribbean Leukaemia Trust
  Anthony Nolan Bone Marrow Trust
  Black Health Agency
  Bloodwise
  Cancer52
  Cancer Black Care
  Cancer Equality
  Chronic Lymphocytic Leukaemia Support Association
  Chronic Myeloid Leukaemia Support Group
  CMV Action
  DKMS
  Equalities National Council
  HAWC
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Leukaemia Cancer Society
  Leukaemia Care
  Lymphoma Association
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  Primary Immunodeficiency UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  UK Primary Immunodeficiency Network
Professional groups British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Institute of Radiology
  British society of Immunology
  British Psychosocial Oncology Society (BPOS)
  British Transplantation Society
  Cancer Research UK
  NHS Blood and Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiology
  The British Society for Haematology
  UK Chronic Lymphocytic Leukaemia Forum
  UK Clinical Pharmacy Association
  UK Health Forum

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Actavis (aciclovir, valaciclovir)
  Accord Healthcare (valganciclovir)
  Aurobindo (valaciclovir, valganciclovir)
  Clinigen (foscarnet)
  GlaxoSmithKline (aciclovir, valaciclovir)
  Hospira (aciclovir)
  Roche Products (valganciclovir)
  Rosemont (aciclovir)
  Sun pharmaceutical (acyclovir, valacicilovir)
  Thame Labratories (aciclovir)
  Thorton & Ross (aciclovir)
  Wockhardt (aciclovir)
General commentators All Wales Therapeutic and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  British Society of Blood and Marrow Transplantation
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association for Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
  United Kingdom National Screening Committee
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Haematological Malignancies Group
  European Group for Blood and Marrow Transplantation
  Leuka
  Leukaemia Busters
  Lymphoma Research Trust
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
09 January 2018 Invitation to participate
14 July 2017 - 11 August 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance